Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$11.64−0.27 (-2.27%)
Close on Nov 18, 2026Market cap $1.51BP/E –Yield –
Mesoblast shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Mesoblast's shares outstanding was 942M at Jun 30, 2023. For fiscal 2026 it was 1.29B, up 7.2% from the year before. Over ten years it grew 13.5% a year on average. The highest annual figure on record is 1.29B in fiscal 2026.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | 1.29B | +7.2% |
| FY2025 | Jun 30, 2025 | 1.21B | +22.4% |
| FY2024 | Jun 30, 2024 | 987M | +26.9% |
| FY2023 | Jun 30, 2023 | 778M | +13.9% |
| FY2022 | Jun 30, 2022 | 683M | +12.9% |
| FY2021 | Jun 30, 2021 | 605M | +14.4% |
| FY2020 | Jun 30, 2020 | 529M | +7.0% |
| FY2019 | Jun 30, 2019 | 494M | +6.2% |
| FY2018 | Jun 30, 2018 | 466M | +16.7% |
| FY2017 | Jun 30, 2017 | 399M | +9.6% |
| FY2016 | Jun 30, 2016 | 364M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | 942M | +19.9% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | 737M | +13.4% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | 737M | +13.7% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | 696M | +7.4% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | 786M | +21.4% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | 650M | +7.5% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | 648M | +10.5% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | 648M | +11.3% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | 647M | +19.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | 604M | +12.4% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | 586M | +9.7% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | 582M | +16.7% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | 544M | +9.0% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | 538M | +7.7% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | 534M | +8.7% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | 499M | +4.2% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | 499M | +5.2% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | 499M | +5.5% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | 492M | +4.3% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | 479M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | 474M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | 473M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 471M | – |
See a number that looks wrong?